Related references
Note: Only part of the references are listed.Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia
Khalaf Kridin et al.
AUTOIMMUNITY REVIEWS (2020)
Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases
Md Yuzaiful Md Yusof et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study
G. Boleto et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2018)
Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab
Evangelos A. A. Christou et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2017)
Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies
Jon Thorkell Einarsson et al.
CLINICAL RHEUMATOLOGY (2017)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease
Darren M. Roberts et al.
JOURNAL OF AUTOIMMUNITY (2015)
Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years
Ronald F. van Vollenhoven et al.
JOURNAL OF RHEUMATOLOGY (2015)
Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients
Ronald F. van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics
Inmaculada De La Torre et al.
RHEUMATOLOGY (2012)
The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis
Ithamar Heber Brinkman et al.
EXPERT OPINION ON DRUG SAFETY (2011)
Risk Factors for Severe Infections in Patients With Rheumatoid Arthritis Treated With Rituximab in the AutoImmunity and Rituximab Registry
J. -E. Gottenberg et al.
ARTHRITIS AND RHEUMATISM (2010)
Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials
Ronald F. van Vollenhoven et al.
JOURNAL OF RHEUMATOLOGY (2010)
Serum Immunoglobulins and Risk of Infection: How Low Can You Go?
Daniel E. Furst
SEMINARS IN ARTHRITIS AND RHEUMATISM (2009)
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis
Edward Keystone et al.
ARTHRITIS AND RHEUMATISM (2007)
Share Paper
